Welcome to our dedicated page for BioRegenx news (Ticker: BRGX), a resource for investors and traders seeking the latest updates and insights on BioRegenx stock.
BioRegenx, Inc. reports health-technology developments in non-invasive diagnostics and predictive analytics for microvascular and metabolic health. Its updates center on GlycoCheck®, distributed through Microvascular Health Solutions under an exclusive worldwide license, and DocSun technology that uses optical sensors and deep-learning algorithms for non-contact vital-sign detection.
Company news also covers public-company reporting, auditor transition, governance standards and securities-law matters following its merger with Findit, Inc. The recurring disclosure themes connect BioRegenx's diagnostics portfolio with AI-enabled physiological measurement and corporate compliance activity.
BioRegenx (OTC: BRGX) announced a series of corporate and technology milestones on Dec 9, 2025. Key actions include engaging a new PCAOB-registered auditor, finalizing an exclusive worldwide license for the clinically validated GlycoCheck vascular diagnostic system, completing integration of the DocSun AI non-contact vital-sign platform, and engaging an investment bank to pursue planned 2026 initiatives.
GlycoCheck is supported by 147 peer-reviewed studies and generates recurring revenue for the company; DocSun provides an SDK and has executed multiple LOIs to explore third-party integrations. The company said it aims to combine GlycoCheck clinical data with DocSun AI to develop predictive vascular and metabolic-health analytics while noting no assurances on regulatory approvals or commercialization outcomes.